Notable Labs is a functional precision medicine company that leverages automation, machine learning and high-throughput flow cytometry to perform drug sensitivity screening on fresh primary patient samples. At Notable, we use this state-of-the-art technology to determine what types of drugs and drug combinations might be useful to patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic dysplastic syndrome (MDS).
For biotech and pharmaceutical companies, we leverage our platform to predict responses to potential therapies and determine which will be most effective for specific cancers. Our work is centered around identifying the right patient population to enhance selection for potential clinical trials, effective drug combinations, and biomarkers to enable pharmaceutical companies to get new therapies to patients faster.
Notable was founded by Matt De Silva in a last attempt to save the life of one patient — his father Mark, who unfortunately passed away from glioblastoma in 2015. Since then, Notable has grown into a company on the verge of transforming the way we develop cancer drugs and identify therapies for patients with blood cancers.